男性骨质疏松症。
Male osteoporosis.
机构信息
Department of Medicine, Division of Endocrinology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
出版信息
Endocrinol Metab Clin North Am. 2012 Sep;41(3):629-41. doi: 10.1016/j.ecl.2012.05.001. Epub 2012 Jun 17.
Abstract
Osteoporosis is now recognized as a major threat to health in aging men. Morbidity and mortality, particularly following hip fracture, are substantial. Although trabecular bone loss starts in early adulthood, loss of cortical bone only seems to occur from midlife onwards. Declining bioavailable estradiol levels plays an integral role in male age-associated bone loss. Both pharmacologic and supportive care interventions are important for optimal care in men at an increased fracture risk.
摘要
骨质疏松症现在被认为是老年男性健康的主要威胁。发病率和死亡率，特别是髋部骨折后，相当高。尽管小梁骨丢失始于成年早期，但皮质骨丢失似乎只发生在中年以后。生物利用度雌二醇水平的下降在男性与年龄相关的骨丢失中起着重要作用。对于骨折风险增加的男性，药物和支持性护理干预都是优化护理的重要措施。
相似文献
1
Male osteoporosis.男性骨质疏松症。
Endocrinol Metab Clin North Am. 2012 Sep;41(3):629-41. doi: 10.1016/j.ecl.2012.05.001. Epub 2012 Jun 17.
2
The Pathophysiology and Treatment of Osteoporosis.骨质疏松症的病理生理学与治疗
Clin Ther. 2015 Aug;37(8):1837-50. doi: 10.1016/j.clinthera.2015.06.006. Epub 2015 Jul 7.
3
Data from extension trials: denosumab and zoledronic acid.延长试验数据：地舒单抗和唑来膦酸。
Curr Osteoporos Rep. 2012 Mar;10(1):16-21. doi: 10.1007/s11914-011-0082-z.
4
One year in review 2018: progress in osteoporosis treatment.2018 年回顾：骨质疏松症治疗进展。
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):948-958. Epub 2018 Dec 6.
5
[Etiopathogenesis and treatment of osteoporosis and fractures in adult males].成年男性骨质疏松症及骨折的病因发病机制与治疗
Med Clin (Barc). 2011 Nov 26;137(14):656-62. doi: 10.1016/j.medcli.2011.01.009. Epub 2011 Mar 21.
6
Parkinson's disease and osteoporosis.帕金森病与骨质疏松症。
Age Ageing. 2013 Mar;42(2):156-62. doi: 10.1093/ageing/afs161. Epub 2012 Nov 6.
7
Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.男性雄激素剥夺治疗中骨质疏松的治疗阈值：T 评分与 FRAX。
Osteoporos Int. 2010 Apr;21(4):647-53. doi: 10.1007/s00198-009-0984-0. Epub 2009 Jun 17.
8
[[Antiresorptive agents in the treatment of osteoporosis].[抗吸收剂在骨质疏松症治疗中的应用]
Reumatizam. 2014;61(2):89-94.
9
Male osteoporosis: do sex steroids really benefit bone health in men?男性骨质疏松症：性类固醇真的对男性骨骼健康有益吗？
Joint Bone Spine. 2011 Dec;78 Suppl 2:S191-6. doi: 10.1016/S1297-319X(11)70003-3.
10
Diagnosis and treatment of osteoporosis in older adults.老年人骨质疏松症的诊断与治疗。
Endocrinol Metab Clin North Am. 2013 Jun;42(2):305-17. doi: 10.1016/j.ecl.2013.02.007. Epub 2013 Apr 13.
引用本文的文献
1
Optimization of Peri-Implant Bone Repair in Estrogen-Deficient Rats on a Cafeteria Diet: The Combined Effects of Systemic Risedronate and Genistein-Functionalized Implants.在食用自助饮食的雌激素缺乏大鼠中优化种植体周围骨修复：全身性利塞膦酸盐与染料木黄酮功能化种植体的联合作用
Materials (Basel). 2025 Feb 2;18(3):662. doi: 10.3390/ma18030662.
2
Paternal age, de novo mutations, and offspring health? New directions for an ageing problem.父亲年龄、新生突变与后代健康？老龄化问题的新方向。
Hum Reprod. 2024 Dec 1;39(12):2645-2654. doi: 10.1093/humrep/deae230.
3
Analysis of factors related to osteoporotic vertebral fracture in prostate cancer patients.前列腺癌患者骨质疏松性椎体骨折相关因素分析
Discov Oncol. 2024 Feb 13;15(1):34. doi: 10.1007/s12672-024-00886-5.
4
Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis.全身利塞膦酸钠与局部治疗协同作用对去卵巢大鼠种植体周围修复的影响：生物力学和分子分析。
Int J Mol Sci. 2023 Nov 10;24(22):16153. doi: 10.3390/ijms242216153.
5
Bone health assessment in adults with fragility fracture risk factors between 2002-2014: a retrospective cohort study.2002年至2014年间有脆性骨折风险因素的成年人的骨骼健康评估：一项回顾性队列研究。
BJGP Open. 2024 Apr 25;8(1). doi: 10.3399/BJGPO.2023.0084. Print 2024 Apr.
6
Evaluation of Vitamin D isolated or Associated with Teriparatide in Peri-Implant Bone Repair in Tibia of Orchiectomized Rats.维生素D单独或与特立帕肽联合应用对去势大鼠胫骨种植体周围骨修复的评估
Biology (Basel). 2023 Jan 31;12(2):228. doi: 10.3390/biology12020228.
7
Prevalence and Distribution of Osteopenia in Chinese Population: A System Review and Meta-Analysis.中国人群骨质减少的患病率及分布：一项系统评价和荟萃分析
Iran J Public Health. 2022 Nov;51(11):2435-2448. doi: 10.18502/ijph.v51i11.11161.
8
Bone health in transgender people: a narrative review.跨性别者的骨骼健康：一项叙述性综述。
Ther Adv Endocrinol Metab. 2022 May 27;13:20420188221099346. doi: 10.1177/20420188221099346. eCollection 2022.
9
A Radiological Assessment of the Prevalence of Osteoporosis in Male Patients Seen in a South African Hospital: A Retrospective Analysis.南非一家医院男性患者骨质疏松症患病率的放射学评估：一项回顾性分析。
J Osteoporos. 2022 May 4;2022:1238927. doi: 10.1155/2022/1238927. eCollection 2022.
10
Effect of Topical PTH 1-34 Functionalized to Biogran in the Process of Alveolar Repair in Rats Submitted to Orchiectomy.经睾丸切除的大鼠肺泡修复过程中，局部应用功能化至生物颗粒的甲状旁腺激素1-34的效果。
Materials (Basel). 2021 Dec 28;15(1):207. doi: 10.3390/ma15010207.
本文引用的文献
1
Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis.临床综述。男性与低骨量相关骨折风险因素：系统综述和荟萃分析。
J Clin Endocrinol Metab. 2012 Jun;97(6):1861-70. doi: 10.1210/jc.2011-3058. Epub 2012 Mar 30.
2
Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis.临床综述。预防脆性骨折的药物治疗效果比较：系统评价和网络荟萃分析。
J Clin Endocrinol Metab. 2012 Jun;97(6):1871-80. doi: 10.1210/jc.2011-3060.
3
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.双膦酸盐和男性糖皮质激素性骨质疏松症：唑来膦酸与利塞膦酸钠随机对照试验的结果。
Bone. 2012 Jan;50(1):289-95. doi: 10.1016/j.bone.2011.10.024. Epub 2011 Oct 29.
4
The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density.2011 年 IOM 关于北美维生素 D 和钙需求量的报告：为治疗低骨密度患者的医护人员提供的临床启示。
J Clin Densitom. 2011 Apr-Jun;14(2):79-84. doi: 10.1016/j.jocd.2011.03.004.
5
Towards a diagnostic and therapeutic consensus in male osteoporosis.男性骨质疏松症的诊断与治疗共识。
Osteoporos Int. 2011 Nov;22(11):2789-98. doi: 10.1007/s00198-011-1632-z. Epub 2011 Apr 21.
6
Secular trends in the incidence of hip and other osteoporotic fractures.髋部和其他骨质疏松性骨折发病率的长期变化趋势。
Osteoporos Int. 2011 May;22(5):1277-88. doi: 10.1007/s00198-011-1601-6. Epub 2011 Apr 2.
7
Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system.在美国综合医疗服务体系中，髋部骨折后骨质疏松的检测和治疗。
Osteoporos Int. 2011 Dec;22(12):2973-80. doi: 10.1007/s00198-011-1536-y. Epub 2011 Jan 27.
8
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.医学研究所 2011 年关于钙和维生素 D 的膳食参考摄入量报告：临床医生需要了解的内容。
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29.
9
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?雌激素缺乏与骨质疏松症发病机制的一元论模型：是否需要修订？
J Bone Miner Res. 2011 Mar;26(3):441-51. doi: 10.1002/jbmr.262.
10
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.唑来膦酸 5mg 每年静脉输注 1 次与每周口服 70mg 阿仑膦酸钠治疗男性骨质疏松症的疗效和安全性：一项随机、多中心、双盲、阳性药物对照研究。
J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.
Zotero 插件